Robert P. Giugliano, MD, FACC

Robert Giugliano

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Daiichi Sankyo(SIGNIFICANT), CVS Caremark(MODEST), Amgen(SIGNIFICANT), Esperion(MODEST), Servier(MODEST), SAJA Pharmaceutics(MODEST), Samsung(MODEST), Pfizer(SIGNIFICANT), Centrix(MODEST), Medscape(SIGNIFICANT), Voxmedia(MODEST), Dr. Reddy's Laboratories Inc.(MODEST), Hengrui(MODEST), Sanofi-Aventis(SIGNIFICANT), Menarini(SIGNIFICANT), CSL Behring (MODEST), Janssen Pharmaceuticals, Inc(MODEST), Labcorp(MODEST), Novartis Corporation(MODEST) RESEARCH/RESEARCH GRANTS: Amgen(SIGNIFICANT), Amgen(SIGNIFICANT), Amgen(SIGNIFICANT), Anthos Therapeutics(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Gilead Sciences, Inc. (MODEST), Inari(SIGNIFICANT), PhaseBio Pharmaceuticals(SIGNIFICANT), Medical Education Resources(SIGNIFICANT), Merck(MODEST), Shanghai Medical Telescope(MODEST), St. Lukes Hospital System - Kansas City(SIGNIFICANT)

View Full Disclosure